433 related articles for article (PubMed ID: 36430974)
21. Programmed Death Receptor Ligand One Expression May Independently Predict Survival in Patients With Non-Small Cell Lung Carcinoma Brain Metastases Receiving Immunotherapy.
Hulsbergen AFC; Mammi M; Nagtegaal SHJ; Lak AM; Kavouridis V; Smith TR; Iorgulescu JB; Mekary RA; Verhoeff JJC; Broekman MLD; Phillips JG
Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):258-267. PubMed ID: 32335185
[TBL] [Abstract][Full Text] [Related]
22. The Prognostic Value of Circulating Soluble Programmed Death Ligand-1 in Cancers: A Meta-Analysis.
Huang P; Hu W; Zhu Y; Wu Y; Lin H
Front Oncol; 2020; 10():626932. PubMed ID: 33718120
[TBL] [Abstract][Full Text] [Related]
23. Prognostic value of soluble programmed cell death ligand-1 (sPD-L1) in lymphoma: a systematic review and meta-analysis.
Ding Y; Sun C; Hu L; Xiong S; Zhai Z
Ann Hematol; 2023 Sep; 102(9):2425-2434. PubMed ID: 37382610
[TBL] [Abstract][Full Text] [Related]
24. The combination of soluble forms of PD-1 and PD-L1 as a predictive marker of PD-1 blockade in patients with advanced cancers: a multicenter retrospective study.
Kurosaki T; Chamoto K; Suzuki S; Kanemura H; Mitani S; Tanaka K; Kawakami H; Kishimoto Y; Haku Y; Ito K; Sato T; Suminaka C; Yamaki M; Chiba Y; Yaguchi T; Omori K; Kobayashi T; Nakagawa K; Honjo T; Hayashi H
Front Immunol; 2023; 14():1325462. PubMed ID: 38149256
[TBL] [Abstract][Full Text] [Related]
25. Circulating miRNAs and PD-L1 Tumor Expression Are Associated with Survival in Advanced NSCLC Patients Treated with Immunotherapy: a Prospective Study.
Boeri M; Milione M; Proto C; Signorelli D; Lo Russo G; Galeone C; Verri C; Mensah M; Centonze G; Martinetti A; Sottotetti E; Pastorino U; Garassino MC; Sozzi G
Clin Cancer Res; 2019 Apr; 25(7):2166-2173. PubMed ID: 30617131
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of PD-1/PD-L1 Inhibitors versus Chemotherapy in Lung Cancer with Brain Metastases: A Systematic Review and Meta-Analysis.
Yang X; Zeng Y; Tan Q; Huang Z; Jia J; Jiang G
J Immunol Res; 2022; 2022():4518898. PubMed ID: 35637793
[TBL] [Abstract][Full Text] [Related]
27. Prognostic significance of circulating soluble programmed death ligand-1 in patients with solid tumors: A meta-analysis.
Wei W; Xu B; Wang Y; Wu C; Jiang J; Wu C
Medicine (Baltimore); 2018 Jan; 97(3):e9617. PubMed ID: 29504990
[TBL] [Abstract][Full Text] [Related]
28. Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non-Small-cell Lung Cancer.
Okuma Y; Wakui H; Utsumi H; Sagawa Y; Hosomi Y; Kuwano K; Homma S
Clin Lung Cancer; 2018 Sep; 19(5):410-417.e1. PubMed ID: 29859759
[TBL] [Abstract][Full Text] [Related]
29. [The efficacy and prognostic factors of immunotherapy in advanced non-small cell lung cancer patients with different driver gene mutations].
Ma SX; Ma N; Han J; He Z; Wang L; Wang Q
Zhonghua Yi Xue Za Zhi; 2022 Apr; 102(13):922-929. PubMed ID: 35385963
[No Abstract] [Full Text] [Related]
30. Biomarkers predicting clinical outcomes in nasopharyngeal cancer patients receiving immune checkpoint inhibitors: A systematic review and meta-analysis.
Qian X; Chen H; Tao Y
Front Immunol; 2023; 14():1146898. PubMed ID: 37063822
[TBL] [Abstract][Full Text] [Related]
31. Prognostic value of soluble programmed cell death ligand-1 in patients with non-small-cell lung cancer: a meta-analysis.
Wang Y; He H
Immunotherapy; 2022 Aug; 14(12):945-956. PubMed ID: 35822688
[No Abstract] [Full Text] [Related]
32. The Prognostic Significance of Soluble Programmed Death Ligand 1 Expression in Cancers: A Systematic Review and Meta-analysis.
Ding Y; Sun C; Li J; Hu L; Li M; Liu J; Pu L; Xiong S
Scand J Immunol; 2017 Nov; 86(5):361-367. PubMed ID: 28930374
[TBL] [Abstract][Full Text] [Related]
33. Prognostic value of programmed cell death ligand 1 (PD-L1) for hepatocellular carcinoma: a meta-analysis.
Li XS; Li JW; Li H; Jiang T
Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32255189
[TBL] [Abstract][Full Text] [Related]
34. Predictive effect of PD-L1 expression for immune checkpoint inhibitor (PD-1/PD-L1 inhibitors) treatment for non-small cell lung cancer: A meta-analysis.
Zhang B; Liu Y; Zhou S; Jiang H; Zhu K; Wang R
Int Immunopharmacol; 2020 Mar; 80():106214. PubMed ID: 31982822
[TBL] [Abstract][Full Text] [Related]
35. The Change of Soluble Programmed Cell Death-Ligand 1 in Glioma Patients Receiving Radiotherapy and Its Impact on Clinical Outcomes.
Ding XC; Wang LL; Zhu YF; Li YD; Nie SL; Yang J; Liang H; Weichselbaum RR; Yu JM; Hu M
Front Immunol; 2020; 11():580335. PubMed ID: 33224142
[TBL] [Abstract][Full Text] [Related]
36. Prognostic Value of Soluble Programmed Cell Death Ligand-1 (sPD-L1) in Various Cancers: A Meta-analysis.
Li X; Zheng Y; Yue F
Target Oncol; 2021 Jan; 16(1):13-26. PubMed ID: 33222017
[TBL] [Abstract][Full Text] [Related]
37. Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma.
Han X; Gu YK; Li SL; Chen H; Chen MS; Cai QQ; Deng HX; Zuo MX; Huang JH
J Cancer Res Clin Oncol; 2019 Feb; 145(2):303-312. PubMed ID: 30267213
[TBL] [Abstract][Full Text] [Related]
38. Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study.
Tiako Meyo M; Jouinot A; Giroux-Leprieur E; Fabre E; Wislez M; Alifano M; Leroy K; Boudou-Rouquette P; Tlemsani C; Khoudour N; Arrondeau J; Thomas-Schoemann A; Blons H; Mansuet-Lupo A; Damotte D; Vidal M; Goldwasser F; Alexandre J; Blanchet B
Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32085544
[TBL] [Abstract][Full Text] [Related]
39. Expression of Programmed Cell Death Ligand 1 as a Predictive Biomarker in Metastatic Urothelial Carcinoma Patients Treated with First-line Immune Checkpoint Inhibitors Versus Chemotherapy: A Systematic Review and Meta-analysis.
Rizzo A; Mollica V; Massari F
Eur Urol Focus; 2022 Jan; 8(1):152-159. PubMed ID: 33516645
[TBL] [Abstract][Full Text] [Related]
40. Soluble programmed cell death ligand 1 predicts prognosis for gastric cancer patients treated with nivolumab: Blood-based biomarker analysis for the DELIVER trial.
Kawakami H; Sunakawa Y; Inoue E; Matoba R; Noda K; Sato T; Suminaka C; Yamaki M; Sakamoto Y; Kawabata R; Ishiguro A; Akamaru Y; Kito Y; Yabusaki H; Matsuyama J; Takahashi M; Makiyama A; Hayashi H; Chamoto K; Honjo T; Nakagawa K; Ichikawa W; Fujii M
Eur J Cancer; 2023 May; 184():10-20. PubMed ID: 36889037
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
